Dual blockade of the EGFR and COX-2 pathways: a phase II trial of cetuximab and celecoxib in patients with chemotherapy refractory metastatic colorectal cancer.

Chan E, Lafleur B, Rothenberg ML, Merchant N, Lockhart AC, Trivedi B, Chung CH, Coffey RJ, Berlin JD
Am J Clin Oncol. 2011 34 (6): 581-6

PMID: 21217396 · PMCID: PMC3133812 · DOI:10.1097/COC.0b013e3181fe46a1

MeSH Terms (21)

Animals Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols Celecoxib Cetuximab Colorectal Neoplasms Cyclooxygenase 2 Disease-Free Survival ErbB Receptors Female Humans Male Mice Mice, Nude Neoplasm Metastasis Neoplasm Staging Pyrazoles Signal Transduction Sulfonamides Xenograft Model Antitumor Assays

Connections (5)

This publication is referenced by other Labnodes entities: